Perspectives: PEACE-3 in Context of Current Landscape
Evan Y. Yu, MD, discusses how the PEACE-3 study data may be practice-changing in specific scenarios for androgen receptor pathway inhibitor (ARPI)–naive metastatic castration-resistant prostate cancer (mCRPC), particularly in patients who have not received prior androgen receptor pathway inhibitors (ARPIs) or abiraterone (ABI), considering how the findings may influence treatment decisions in light of the current landscape. He also addresses how the combination of enzalutamide (ENZA) and radium-223 (Ra-223) could be considered in the management of symptomatic mCRPC, while discussing the caveats of the ALSYMPCA study, particularly its conduct in an era prior to the introduction of ABI and ENZA. Additionally, he explores the role of bone-protecting agents and the importance of bone density scans for patients receiving an ARPI and Ra-223 in combination.
Video content above is prompted by the following:
- Do you consider the PEACE-3 data practice changing? In what scenarios would you consider use of ENZA in combination with Ra-223?
- Given the current treatment landscape for prostate cancer, how applicable to practice are the PEACE-3 findings?
- What types of patients will not have received a prior ARPI/ABI at mCRPC diagnosis?
- What if this patient was symptomatic? What other options might you consider?
- What are the caveats around data from the phase 3 ALSYMPCA study of RA-223 for metastatic castration-resistant prostate cancer (mCRPC)? ) (eg, conducted in era before introduction of ABI and ENZA)?
- What has been learned about use of bone-protectingbone protecting agents and bone density scans for patients receiving an ARPI in combination with Ra-223?
